Edwards Lifesciences Surges to 197th in Trading Volume with $567 Million Turnover Despite Stock Price Decline

On July 24, 2025, Edwards Lifesciences (EW) experienced a significant trading day with a turnover of $567 million, marking a 40.74% increase from the previous day. This surge placed Edwards Lifesciences at the 197th position in terms of trading volume for the day. However, despite the high trading volume, the stock price of Edwards Lifesciences declined by 1.44%.

Edwards Lifesciences reported a strong second quarter, with sales increasing by nearly 12%. The company's adjusted earnings per share were $0.67, surpassing analyst expectations of $0.62. Revenue for the quarter reached $1.53 billion, an 11.9% increase from the previous year. This strong performance led to a 7% increase in after-hours trading following the release of the Q2 results.

The company's Transcatheter Aortic Valve Replacement (TAVR) sales grew by 8.9%, contributing to the overall revenue increase. The SAPIEN platform, a key product in Edwards Lifesciences' portfolio, saw unrivaled adoption, driving the 8.9% year-over-year growth in Q2 revenue. The platform's recent FDA and CE Mark approvals further solidified its market position.

Despite the earnings decline of more than 4% year over year, the company's sales climbed 11.9%. On an adjusted basis, sales rose 10.6%. The company's bottom line totaled $333.2 million, or $0.56 per share, compared to $366.3 million, or $0.61 per share, in the same period last year. Excluding items, Edwards Lifesciences reported adjusted earnings of $391.8 million or $0.67 per share for the period.

Edwards Lifesciences has increased its full-year sales growth guidance following the strong Q2 results. The company's next quarter EPS guidance is $0.54 - $0.60, with revenue guidance of $1.46 - $1.54 billion. For the full year, EPS guidance is $2.40 - $2.50, with revenue guidance of $5.9 - $6.1 billion. This positive outlook reflects the company's confidence in its continued growth and market leadership.